How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD
| Image |  |
|---|---|
| Description | scientific article published on 01 August 2018 |
| Author/s |
author: Bruce R Blazar Samantha M Jaglowski |
| Publication date | August 1, 2018 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |